BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

Abstract. Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other ...

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other ...

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

Indeed, Bevacizumab in combination with a triplet or a doublet chemotherapy is considered the best options in patients with BRAF mt tumors. The recent results ...

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

In RCTs, an overall response was reported in 23% of the patients treated with BRAF inhibitor-based regimens compared to 2.5% with control ...

Immune check point inhibitors in BRAF mutated metastatic colorectal ...

Metastatic colorectal cancers with BRAF mutation are a class of tumors that have a poor prognosis compared to wild type patients. Even if this ...

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint ...

Molecular profiling of BRAF-V600E-mutant metastatic colorectal ...

BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type ...

RAS and BRAF in metastatic colorectal cancer management - Gong

BRAF mutations have also been shown to predict lack of clinically meaningful benefit to anti-EGFR therapy in mCRC. Mechanisms of resistance to EGFR blockade in ...

Management of BRAF-mutant metastatic colorectal cancer: a review ...

(B) Monotherapy with a BRAF inhibitor (encorafenib, dabrafenib, vemurafenib) blocks the activity of mutated BRAF, subsequently removing the ...

Genomic profiles of BRAF inhibitor resistance mechanisms in ...

Background: BRAF mutations are present in 5-10% of metastatic colorectal cancers (mCRCs). Patients with mCRC whose tumors harbor BRAF V600 ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - Frontiers

Around 8–12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, which is ...

Targeting BRAF in metastatic colorectal cancer - ScienceDirect.com

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the ...

BRAF mutant colorectal cancer as a distinct subset of colorectal cancer

In 2011 vemurafenib, a protein kinase inhibitor of BRAFV600E was approved by the FDA for the treatment of metastatic melanoma after promising results in phase 3 ...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated ...

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 ...

BRAF and KRAS mutations in metastatic colorectal cancer

On the one hand, this mechanism explains why the single BRAF inhibitor has an antitumor effect in melanoma but not in mCRC. Melanoma cells ...

BRAF mutant colorectal cancer: prognosis, treatment, and new ...

In contrast to other malignances such as BRAF mutant melanoma, efficacy observed with BRAF inhibitors in monotherapy in mCRC is poor. Several mechanisms of ...

Response to Anti-EGFR Therapy in Patients with BRAF non-V600 ...

In metastatic colorectal cancer (mCRC), BRAF mutations consist of 2/3 class 1 and 1/3 class 2 and 3 alterations. The class 2 and 3 BRAF mutants do not respond ...

Phase IB Study of Vemurafenib in Combination with Irinotecan and ...

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, ...

Targeting BRAF in metastatic colorectal cancer

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the ...

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC.